Abiraterone acetate plus prednisone (AA+P) without continuing LHRH-therapy in patients with metastatic chemotherapy: Naive castrations-resistant prostate cancer—Results from the SPARE-trial (NCT02077634).

Carsten H. Ohlmann,Christoph Ruessel,Roger Zillmann,E. Hellmis,Henrik Suttmann,Martin Janssen,Jan Marin,Johannes Dahm,Andreas Hübner,Jochen Gleissner,Michael T. Scheffler,Susan Feyerabend,Jens Telle,Peter Jähnig,Michelle Jäschke,Joerg Klier

Abiraterone acetate plus prednisone (AA+P) without continuing LHRH-therapy in patients with metastatic chemotherapy: Naive castrations-resistant prostate cancer—Results from the SPARE-trial (NCT02077634).

2019

Carsten H. Ohlmann
Christoph Ruessel
Roger Zillmann
E. Hellmis
Henrik Suttmann
Martin Janssen
Jan Marin
Johannes Dahm
Andreas Hübner
Jochen Gleissner
Michael T. Scheffler
Susan Feyerabend
Jens Telle
Peter Jähnig
Michelle Jäschke
Joerg Klier

5046Background: The value of continuation of androgen deprivation therapy (ADT) in metastatic castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Especi...

Keywords:

Abiraterone acetate
Prostate cancer
Pathology
Oncology
Prednisone
Medicine
Chemotherapy
Internal medicine
in patient
Androgen deprivation therapy
chemotherapy naive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations